Literature DB >> 20646850

Feasibility of helical tomotherapy for debulking irradiation before stem cell transplantation in malignant lymphoma.

Cyrus Chargari1, Jean-Paul Vernant, Jerome Tamburini, Sofia Zefkili, Maryse Fayolle, Francois Campana, Alain Fourquet, Youlia M Kirova.   

Abstract

PURPOSE: Preliminary clinical experience has suggested that radiation therapy (RT) may be effectively incorporated into conditioning therapy before transplant for patients with refractory/relapsed malignant lymphoma. We investigated the feasibility of debulking selective lymph node irradiation before autologous and/or allogeneic stem cell transplantation (SCT) using helical tomotherapy (HT). METHODS AND MATERIALS: Six consecutive patients with refractory malignant lymphoma were referred to our institution for salvage HT before SCT. All patients had been previously heavily treated but had bulky residual tumor despite chemotherapy (CT) intensification. Two patients had received previous radiation therapy. HT delivered 30-40 Gy in the involved fields (IF), using 6 MV photons, 2 Gy per daily fraction. Total duration of treatment was 28 to 35 days.
RESULTS: Using HT, doses to critical organs (heart, lungs, esophagus, and parotids) were significantly decreased and highly conformational irradiation could be delivered to all clinical target volumes. HT delivery was technically possible, even in patients with lesions extremely difficult to irradiate in other conditions or in patients with previous radiation therapy. No Grade 2 or higher toxicity occurred. Four months after the end of HT, 5 patients experienced complete clinical, radiologic, and metabolic response and were subsequently referred for SCT.
CONCLUSIONS: By more effectively sparing critical organs, HT may contribute to improving the tolerance of debulking irradiation before allograft. Quality of life may be preserved, and doses to the heart may be decreased. This is particularly relevant in heavily treated patients who are at risk for subsequent heart disease. These preliminary results require further prospective assessment.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20646850     DOI: 10.1016/j.ijrobp.2010.01.051

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  4 in total

1.  Applications of new irradiation modalities in patients with lymphoma: Promises and uncertainties.

Authors:  Youlia M Kirova; Cyrus Chargari
Journal:  World J Radiol       Date:  2011-03-28

2.  Further developments for improving response and tolerance to irradiation for advanced renal cancer: concurrent (mTOR) inhibitor RAD001 and helical tomotherapy.

Authors:  Youlia M Kirova; Vincent Servois; Cyrus Chargari; Malika Amessis; Marc Zerbib; Philippe Beuzeboc
Journal:  Invest New Drugs       Date:  2010-12-14       Impact factor: 3.850

Review 3.  Pushing the envelope-nonmyeloablative and reduced intensity preparative regimens for allogeneic hematopoietic transplantation.

Authors:  S R Pingali; R E Champlin
Journal:  Bone Marrow Transplant       Date:  2015-05-18       Impact factor: 5.483

Review 4.  Image-guided radiation therapy in lymphoma management.

Authors:  Tony Eng; Chul S Ha
Journal:  Radiat Oncol J       Date:  2015-09-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.